Attention Deficit Hyperactivity Disorder Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Attention Deficit Hyperactivity Disorder stocks.

Attention Deficit Hyperactivity Disorder Stocks Recent News

Date Stock Title
Nov 22 LLY Sanofi Plans to Change Hospital Drug-Discount Program
Nov 22 LLY VKTX Stock Loses Over $1B in a Month: How to Play the Stock?
Nov 22 LLY Investing in Pharma Stocks? Check These 3 Things First
Nov 22 LLY Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry?
Nov 22 LLY Goldman Sachs: Eli Lilly and Company (LLY) Is A Top Growth Investor Stock
Nov 21 ZVRA Zevra Niemann-Pick disease type C drug Miplyffa now available
Nov 21 LLY The FDA Can’t Decide Whether Zepbound Is in Shortage. It’s Good News for Hims & Hers Stock.
Nov 21 ZVRA Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C
Nov 21 LLY Eli Lilly Stock: Unexpected Developments (Rating Downgrade)
Nov 21 LLY Hims & Hers closes up 10% as Lilly tirzepatide compounding dispute resolution delayed
Nov 21 LLY Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
Nov 21 LLY Is Now a Good Time to Buy the Dip in Eli Lilly Stock?
Nov 21 LLY Eli Lilly, Verge announce milestones in ALS collaboration
Nov 21 LLY Versant startup sets out to make a new type of obesity drug
Nov 21 LLY Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop
Nov 20 LLY Jim Cramer on Eli Lilly and Company (LLY): ‘I’m Kind Of Blown Away’
Nov 20 LLY Eli Lilly in pact with Chinese biotech for novel weight loss therapy
Nov 20 LLY More companies covering weight loss drugs for their employees
Nov 20 LLY Weight loss drug makers want more insurance plans to cover Wegovy and Zepbound
Nov 20 LLY China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug
Attention Deficit Hyperactivity Disorder

Attention deficit hyperactivity disorder (ADHD) is a mental disorder of the neurodevelopmental type. It is characterized by difficulty paying attention, excessive activity, or difficulty controlling behavior which is not appropriate for a person's age. The symptoms appear before a person is twelve years old, are present for more than six months, and may cause problems in at least two settings (such as school, home, or recreational activities). In children, problems paying attention may result in poor school performance. Additionally there is an association with other mental disorders and substance misuse. Although it causes impairment, particularly in modern society, many people with ADHD can have sustained attention span for tasks they find interesting or rewarding (known as hyperfocus).Despite being the most commonly studied and diagnosed mental disorder in children and adolescents, the exact cause is unknown in the majority of cases. It affects about 5–7% of children when diagnosed via the DSM-IV criteria and 1–2% when diagnosed via the ICD-10 criteria. As of 2015 it is estimated to affect about 51.1 million people globally. Rates are similar between countries and depend mostly on how it is diagnosed. ADHD is diagnosed approximately two times more often in boys than in girls, although the disorder is often overlooked in girls because their symptoms differ from those of boys. About 30–50% of people diagnosed in childhood continue to have symptoms into adulthood and between 2–5% of adults have the condition. In adults inner restlessness rather than hyperactivity may occur. The condition can be difficult to tell apart from other conditions, as well as to distinguish from high levels of activity that are still within the range of normative behaviors.ADHD management recommendations vary by country and usually involve some combination of counseling, lifestyle changes, and medications. The British guideline only recommends medications as a first-line treatment in children who have severe symptoms and for medication to be considered in those with moderate symptoms who either refuse or fail to improve with counseling, though for adults medications are a first-line treatment. Canadian and American guidelines recommend that medications and behavioral therapy be used together as a first-line therapy, except in preschool-aged children. Stimulant medication therapy is not recommended as a first-line therapy in preschool-aged children in either guideline. Treatment with stimulants is effective for at least 14 months; however, their long term effectiveness is unclear. Adults often develop coping skills which make up for some or all of their impairments.The medical literature has described symptoms similar to those of ADHD since the 18th century. ADHD, its diagnosis, and its treatment have been considered controversial since the 1970s. The controversies have involved clinicians, teachers, policymakers, parents, and the media. Topics include ADHD's causes and the use of stimulant medications in its treatment. Most healthcare providers accept ADHD as a genuine disorder in children and adults, and the debate in the scientific community mainly centers on how it is diagnosed and treated. The condition was officially known as attention-deficit disorder (ADD) from 1980 to 1987, while before this it was known as hyperkinetic reaction of childhood.

Browse All Tags